Work

Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.5_suppl.63

Authors: Robert Connor Chick, Mark B. Faries, Diane F. Hale, Phillip M. Kemp Bohan, Annelies Hickerson, Timothy J. Vreeland, John William Myers, Jessica L. Cindass, Tommy A. Brown, John Robert Hyngstrom, James W. Jakub, Jeffrey J. Sussman, Adam C. Berger, Montaser F. Shaheen, G. Travis Clifton, Thomas Wagner, George Earl Peoples

Institutions: Brooke Army Medical Center, University of Utah, Mayo Clinic, University of Cincinnati, Rutgers Cancer Institute, University of Arizona Cancer Center, Perseus PCI (United States)

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3004873791

Cites:

Cited by: 4

Related to: 10